Since it has become difficult for many biopharmaceutical companies to raise money during the past year and a half, several firms have been forced to cut costs to make remaining cash balances last longer. Drug developers also have restructured and laid off employees as clinical trials and product launches failed to meet expectations, as was the case for FibroGen, Inc. and Amarin Corporation plc, which recently announced restructuring plans and job cuts.
Strategic Shifts In Focus
See the Scrip articles below for more detailed analyses of struggles at Pieris Pharmaceuticals, Inc. and AVROBIO, Inc. and the most recent edition of Deal Watch notes reverse mergers involving troubled firms Neoleukin Therapeutics, Inc. and Frequency Therapeutics Inc.
Pieris Looks For Way Out After AstraZeneca Exits Respiratory Collaboration
In Seeking ‘Strategic Alternatives’ Avrobio Is Confronting Gene Therapy Reality
FibroGen said in a 19 July filing with the US Securities and Exchange Commission (SEC) that the company will implement...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
